In response to receiving a Complete Response Letter (CRL) from the FDA, shares of Evolus(NASDAQ:EOLS), a newly public clinical-stage biotech company focused on aesthetics, sank 31% as of 11:05 a.m. EDT on Wednesday.
Evolus announced today thatits lead compound, DWP-450, received a CRL from the FDA, which is a nice way of saying that it was rejected.....More>>>
La Jolla Pharmaceutical (LJPC) recently announced that it had entered into a financing deal that would help it with the launch of its drug Giapreza. This not only helps the biotech with the commercial launch of the drug, but it also provides cash to fund other products in the pipeline like LJPC-401. That’s why I believe it is a good buy after this funding announcement.
Investment company Summit X, LLC buys iShares Core MSCI Emerging Markets, iShares Core S&P 500, Pimco Dynamic Credit & Mortgage Income Fund, Pimco Dynamic Credit & Mortgage Income Fund, International Business Machines Corp, iShares 7-10 Year Treasury Bond ETF, iShares S&P 500 Value, iShares Core S&P Mid-Cap, VanEck Vectors Gold Miners, Eversource Energy, sells iShares iBoxx $....More>>>
Shares of Ardelyx (NASDAQ:ARDX) got smacked down 19.5% on Tuesday after announcing that it was raising cash two different ways after the bell yesterday.
Perhaps the biotech would have only been down half as much if it had just stuck with one capital-raising endeavor.
Image source: Getty Images.
First, Ardelyx said it raised $50 million through a....More>>>
Biotech investing has always been an inherently risky business. On top of failed trials, recent political headline risk has added an additional reason for investor concern. Biotech investors may have dodged a bullet with Donald Trump emerging as the victor over Hillary Clinton in the 2016 election but they did not escape totally unharmed. The whole biotech sector was crushed in December 2016 when....More>>>
Gilead Sciences’ (NASDAQ:GILD) last quarterly earnings update in February sounded kind of like a broken record. The news in the fourth quarter of 2017 was very similar to Gilead’s results for earlier quarters in the year.
The big biotech will provide an update on its first-quarter performance on Tuesday, May 1, 2018. Will there be more of thesame old story or some new twists?....More>>>
The biotechs and emerging pharma havebeen under pressure from politicians attacking drug prices. That doesn’t mean that there are not some big winners out there. Sometimes the biggest winners are companies most investors have never heard of. Even if you have been a biotech and emerging pharma investor for years, chances are high that you would have never heard of a small outfit called Apricus....More>>>
Biotech company Bioverativ Inc (NASDAQ:BIVV) is being acquired by Sanofi SA (ADR) (NYSE:SNY) for $11.6 billion in cash. The deal puts a 64% premium on the price of BIVV stock, which was up 61% in pre-market activity at 5:15 a.m. today.
Bioverativ focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment....More>>>
Media coverage about Biogen (NASDAQ:BIIB) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable.....More>>>
&l;p&g;&l;img class=&q;dam-image shutterstock size-large wp-image-659769976&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/659769976/960×0.jpg?fit=scale&q; data-height=&q;634&q; data-width=&q;960&q;&g; Shutterstock
It&s;s the unusually diverse nature of the list that&s;s fascinating. Lots of different types of industries and sectors. Some are reasonably well-known, others....More>>>